Stock listing
BMV:LABB Genomma Lab Internacional SAB de CV Acciones
Home listing (BMV) of Genomma Lab Internacional SAB de CV
Follow Genomma Lab Internacional SAB de CV into a list and get an email when it puts out news.
Share price · BMV:LAB/B
$14.46 MXN -0.69 (-4.6%)
Close on Nov 20, 2026
- Day range
- $14.41 – $14.88 MXNNov 20, 2026
- Volume
- 3.16M sharesNov 20, 2026
- Market cap
- $14.14B MXNAt the close on Nov 20, 2026 · price × 977.8M shares outstanding
- 52-week range
- $12.22 – $19.48 MXNLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $54.47M MXNMedian day 3.63M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:GNMLF | $0.85 USD | +0.015 (+1.8%) | 150 | $0.85 | $0.85 | $0.85 | $0.835 | Close on Nov 10, 2026 |
| Frankfurt:GEKA | €0.724 EUR | +0.025 (+3.6%) | — | €0.724 | €0.724 | €0.724 | €0.699 | Close on Nov 5, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · BMV:LAB/B · MXN, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $14.46 | -0.69 | -4.6% | $14.61 | $14.88 | $14.41 | 3,162,570 | |
| $15.15 | -0.02 | -0.1% | $15.23 | $15.52 | $15.00 | 3,821,335 | |
| $15.17 | -0.14 | -0.9% | $15.38 | $15.38 | $15.10 | 3,613,633 | |
| $15.31 | -0.33 | -2.1% | $15.64 | $15.70 | $15.25 | 2,985,853 | |
| $15.64 | +0.01 | +0.1% | $15.58 | $15.79 | $15.53 | 2,990,605 | |
| $15.63 | +0.13 | +0.8% | $15.57 | $15.78 | $15.48 | 3,774,586 | |
| $15.50 | -0.26 | -1.6% | $15.56 | $15.85 | $15.45 | 3,648,665 | |
| $15.76 | -0.18 | -1.1% | $15.86 | $16.15 | $15.64 | 3,517,913 | |
| $15.94 | +0.84 | +5.6% | $15.17 | $16.00 | $15.12 | 3,718,002 | |
| $15.10 | -0.39 | -2.5% | $15.45 | $15.53 | $14.80 | 4,758,769 | |
| $15.49 | +0.38 | +2.5% | $15.19 | $15.62 | $15.11 | 2,851,420 | |
| $15.11 | -0.03 | -0.2% | $15.06 | $15.63 | $14.93 | 4,349,870 | |
| $15.14 | +0.23 | +1.5% | $14.60 | $15.19 | $14.60 | 3,639,970 | |
| $14.91 | +0.42 | +2.9% | $14.54 | $14.97 | $14.48 | 3,340,451 | |
| $14.49 | -0.93 | -6.0% | $15.34 | $15.34 | $14.34 | 4,343,601 | |
| $15.42 | -0.24 | -1.5% | $15.62 | $15.75 | $15.26 | 12,642,171 | |
| $15.66 | +0.33 | +2.2% | $15.40 | $15.70 | $15.20 | 3,725,217 | |
| $15.33 | +0.65 | +4.4% | $14.66 | $15.46 | $14.61 | 4,189,281 | |
| $14.68 | +0.30 | +2.1% | $14.15 | $14.72 | $14.15 | 3,063,954 | |
| $14.38 | +0.11 | +0.8% | $14.34 | $14.49 | $14.12 | 4,294,836 | |
| $14.27 | -0.12 | -0.8% | $14.39 | $14.44 | $14.16 | 3,194,214 | |
| $14.39 | +0.20 | +1.4% | $14.20 | $14.48 | $14.19 | 3,684,005 | |
| $14.19 | +0.40 | +2.9% | $13.77 | $14.30 | $13.77 | 4,586,934 | |
| $13.79 | 0.00 | 0.0% | $13.88 | $14.00 | $13.62 | 3,547,733 | |
| $13.79 | +0.49 | +3.7% | $13.31 | $13.85 | $13.24 | 6,402,715 | |
| $13.30 | +0.18 | +1.4% | $13.02 | $13.40 | $13.00 | 5,634,980 | |
| $13.12 | +0.06 | +0.5% | $13.07 | $13.28 | $13.04 | 3,424,182 | |
| $13.06 | +0.24 | +1.9% | $12.87 | $13.10 | $12.76 | 4,308,452 | |
| $12.82 | -0.01 | -0.1% | $12.79 | $12.88 | $12.70 | 3,746,885 | |
| $12.83 | -0.02 | -0.2% | $12.82 | $12.86 | $12.65 | 3,631,190 | |
| $12.85 | +0.33 | +2.6% | $12.55 | $12.93 | $12.53 | 4,937,813 | |
| $12.52 | -0.31 | -2.4% | $12.83 | $12.86 | $12.43 | 3,630,384 | |
| $12.83 | +0.27 | +2.1% | $12.50 | $12.86 | $12.42 | 5,466,290 | |
| $12.56 | +0.05 | +0.4% | $12.70 | $12.75 | $12.41 | 3,187,582 | |
| $12.51 | -0.28 | -2.2% | $12.85 | $12.85 | $12.37 | 5,084,825 | |
| $12.79 | -0.15 | -1.2% | $12.99 | $13.05 | $12.72 | 2,930,029 | |
| $12.94 | +0.10 | +0.8% | $12.85 | $12.98 | $12.77 | 3,060,236 | |
| $12.84 | +0.01 | +0.1% | $12.92 | $12.94 | $12.70 | 3,202,366 | |
| $12.83 | +0.22 | +1.7% | $12.50 | $12.88 | $12.50 | 4,197,147 | |
| $12.61 | +0.10 | +0.8% | $12.59 | $12.71 | $12.46 | 2,853,396 | |
| $12.51 | +0.19 | +1.5% | $12.40 | $12.62 | $12.36 | 2,718,646 | |
| $12.32 | -0.04 | -0.3% | $12.45 | $12.46 | $12.22 | 6,062,067 | |
| $12.36 | -0.24 | -1.9% | $12.63 | $12.64 | $12.34 | 5,258,976 | |
| $12.60 | +0.28 | +2.3% | $12.35 | $12.62 | $12.25 | 4,195,163 | |
| $12.32 | -0.28 | -2.2% | $12.56 | $12.63 | $12.25 | 3,334,971 | |
| $12.60 | -0.07 | -0.6% | $12.64 | $12.71 | $12.52 | 3,458,226 | |
| $12.67 | -0.07 | -0.5% | $12.77 | $12.84 | $12.60 | 2,229,288 | |
| $12.74 | -0.17 | -1.3% | $12.93 | $12.99 | $12.70 | 3,889,482 | |
| $12.91 | +0.10 | +0.8% | $12.84 | $12.98 | $12.61 | 3,433,300 | |
| $12.81 | -0.41 | -3.1% | $13.21 | $13.21 | $12.71 | 3,611,240 | |
| $13.22 | +0.18 | +1.4% | $13.16 | $13.28 | $12.80 | 854,873 | |
| $13.04 | -0.01 | -0.1% | $13.10 | $13.26 | $12.98 | 6,209,728 | |
| $13.05 | +0.16 | +1.2% | $12.88 | $13.21 | $12.83 | 7,861,880 | |
| $12.89 | -0.25 | -1.9% | $13.15 | $13.15 | $12.81 | 3,449,492 | |
| $13.14 | -0.03 | -0.2% | $13.20 | $13.39 | $13.11 | 3,475,494 | |
| $13.17 | -0.30 | -2.2% | $13.43 | $13.48 | $13.12 | 5,486,099 | |
| $13.47 | -0.08 | -0.6% | $13.47 | $13.67 | $13.38 | 2,514,653 | |
| $13.55 | 0.00 | 0.0% | $13.54 | $13.70 | $13.30 | 3,097,503 | |
| $13.55 | +0.01 | +0.1% | $13.54 | $13.74 | $13.48 | 3,357,937 | |
| $13.54 | -0.01 | -0.1% | $13.52 | $13.65 | $13.36 | 2,365,654 | |
| $13.55 | -0.02 | -0.1% | $13.50 | $13.72 | $13.49 | 2,286,615 | |
| $13.57 | +0.30 | +2.3% | $13.35 | $13.64 | $13.30 | 3,072,467 | |
| $13.27 | -0.16 | -1.2% | $13.46 | $13.71 | $13.25 | 3,865,306 |
Splits
1 split · BMV:LAB/B · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split |
- Ticker
- BMV:LAB/B
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- BMV
- Currency
- MXN
What changed lately
Latest earnings call · Jul 23, 2026
Genomma Lab Internacional SAB de CV (BMV:LAB/B) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Apr 1, 2026
Q3 2026 Earnings Presentation
Earnings · 27 slides
Latest news
LAB/B: Net sales fell 4.9% as FX and weak demand weighed, but LATAM growth and margin gains offset declines
Apr 23, 2026
Closed $17.27 (-6.5%) on Apr 23, 2026
LAB/B: Margins held strong despite sales decline, with recovery and growth initiatives set for 2026
Feb 26, 2026
Closed $17.79 (+2.2%) on Feb 26, 2026
Genomma Lab Internacional SAB de CV on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 2 in the last 12 months · 8 in all · newest Apr 23, 2026 · oldest 2024
- Calls
- 19 calls with a replay · 19 with a transcript · latest Jul 23, 2026
- Decks
- 29 decks · latest Apr 1, 2026
Where Genomma Lab Internacional SAB de CV is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| BMV:LABB · Home listing · This page | BMV | Mexico | MXN |
| BIVA:LABB | BIVA | Mexico | MXN |
| LS Exchange:A0Q4TC | LS Exchange | Germany | EUR |
| Lang & Schwarz:A0Q4TC | Lang & Schwarz | Germany | EUR |
| OTC:GNMLF | OTC | United States | USD |
| Dusseldorf:GEKA | Dusseldorf | Germany | EUR |
| Frankfurt:GEKA | Frankfurt | Germany | EUR |
Valuation
P/E 8.3× against a median of 28.6×: 2nd lowest of 7 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $18.20B MXN
- P/E
- 8.3×
- EV/sales
- 1.1×
- EV/EBITDA
- 4.8×
- Price/book
- 1.2×
- Gross margin
- 62.6%
- Operating margin
- 20.3%
- Net margin
- 10.0%
- Debt to equity
- 0.6×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Genomma Lab Internacional SAB de CV Class B · BMV:LAB/B | US$740.5M | US$953.0M | 8.3× | 1.1× | 4.8× | 1.2× | 10.0% | 0.6× | n/a |
| Dezhan Healthcare Co., Ltd. Class A · SZSE:000813 | US$768.0M | US$680.7M | n/a | 13.0× | n/a | 1.1× | −111.1% | 0.0× | n/a |
| Knight Therapeutics, Inc. · TSX:GUD | US$763.1M | US$683.3M | 68.5× | 1.7× | 10.5× | 1.4× | 2.8% | 0.0× | 0.33 |
| Guizhou Bailing Group Pharmaceutical Co., Ltd. Class A · SZSE:002424 | US$757.0M | US$728.7M | n/a | 2.1× | n/a | 1.6× | −5.5% | 0.0× | n/a |
| Luye Pharma Group Ltd. · HKEX:2186 | US$751.7M | US$1.02B | 8.1× | 1.1× | 3.3× | 0.3× | 9.8% | 0.8× | n/a |
| Ardelyx, Inc. · NASDAQ:ARDX | US$751.6M | US$718.6M | n/a | 1.5× | n/a | 4.6× | −11.8% | 1.5× | 0.88 |
| Bliss GVS Pharma Limited · NSE:BLISSGVS | US$735.1M | US$716.7M | 42.3× | 6.2× | 28.1× | 5.3× | 15.0% | 0.0× | n/a |
| Hunan Fangsheng Pharmaceutical Co., Ltd. Class A · SSE:603998 | US$732.2M | US$694.9M | 14.9× | 2.5× | n/a | 2.7× | 17.4% | 0.0× | n/a |
| Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A · SZSE:002082 | US$729.9M | US$658.8M | n/a | 5.0× | n/a | 1.9× | −20.2% | 0.1× | n/a |
| Zhuzhou Qianjin Pharmaceutical Co., Ltd. Class A · SSE:600479 | US$718.1M | US$612.0M | 13.4× | 1.1× | n/a | 1.5× | 9.5% | 0.0× | n/a |
| Chongqing Pharscin Pharmaceutical Co., Ltd. Class A · SZSE:002907 | US$708.3M | US$620.6M | 50.3× | 4.9× | n/a | 2.7× | 11.0% | 0.0× | n/a |
| Median of the others | US$743.3M | US$689.1M | 28.6× | 2.3× | 10.5× | 1.8× | 6.2% | 0.0× | 0.61 |
Forecasts
Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 21.33 MXN · Analysts' mean
- EPS, year to Dec 2026
- 1.86 · 5 analysts
- Revenue, year to Dec 2026
- 17.81B · 6 analysts
Events
- Next results
- Feb 24, 2027 (expected)
Calls
All 19 calls
| Call | When | Status |
|---|---|---|
| Genomma Lab Internacional SAB de CV (BMV:LAB/B) Q1 2023 Earnings Call | Thu, Apr 27, 2023 · 11:00 AM ET | Replay |
| Genomma Lab Internacional SAB de CV (BMV:LAB/B) Q4 2022 Earnings Call | Thu, Feb 23, 2023 · 11:00 AM ET | Replay |
| Genomma Lab Internacional SAB de CV (BMV:LAB/B) Q3 2022 Earnings Call | Thu, Oct 27, 2022 · 11:00 AM ET | Replay |
| Genomma Lab Internacional SAB de CV (BMV:LAB/B) Q2 2022 Earnings Call | Thu, Jul 28, 2022 · 11:00 AM ET | Replay |
| Genomma Lab Internacional SAB de CV (BMV:LAB/B) Q1 2022 Earnings Call | Thu, Apr 28, 2022 · 11:00 AM ET | Replay |
| Genomma Lab Internacional SAB de CV (BMV:LAB/B) Q4 2021 Earnings Call | Thu, Feb 24, 2022 · 11:00 AM ET | Replay |
| Genomma Lab Internacional SAB de CV (BMV:LAB/B) Q3 2021 Earnings Call | Wed, Oct 27, 2021 · 11:00 PM ET | Replay |
| Genomma Lab Internacional SAB de CV (BMV:LAB/B) Q2 2021 Earnings Call | Wed, Jul 28, 2021 · 11:00 AM ET | Replay |
| Genomma Lab Internacional SAB de CV (BMV:LAB/B) Q1 2021 Earnings Call | Tue, Apr 13, 2021 · 11:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 21, 2026 · After close | +2.1% |
| Q2 2026 | Jul 22, 2026 · After close | −3.5% |
| Q1 2026 | Apr 22, 2026 · After close | −6.5% |
| Q4 2025 | Feb 25, 2026 · After close | +2.2% |
| Q3 2025 | Oct 22, 2025 · After close | +1.3% |
| Q2 2025 | Jul 23, 2025 · After close | −1.2% |
| Q1 2025 | Apr 30, 2025 · Before open | −6.8% |
| Q4 2024 | Feb 19, 2025 · After close | −1.9% |
| Q3 2024 | Oct 23, 2024 · Before open | +0.3% |
| Q2 2024 | Jul 24, 2024 · Before open | −1.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 24, 2024 · After close | +7.9% |
| Q4 2023 | Feb 21, 2024 · After close | +10.1% |
| Q3 2023 | Oct 25, 2023 · After close | +2.6% |
| Q2 2023 | Jul 26, 2023 · After close | +4.1% |
| Q1 2023 | Apr 26, 2023 · After close | +0.6% |
| Q4 2022 | Feb 22, 2023 · After close | −10.0% |
| Q3 2022 | Oct 26, 2022 · After close | +3.7% |
| Q2 2022 | Jul 27, 2022 · After close | −0.4% |
| Q1 2022 | Apr 27, 2022 · After close | −1.2% |
| Q4 2021 | Feb 23, 2022 · After close | −1.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 27 slides | Apr 1, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 29 slides | Apr 1, 2026 |
| Investor Presentation (December 2025) | Investor deck | 32 slides | December 2025 |
| Q3 2025 Earnings Presentation | Earnings | 26 slides | October 2025 |
| Q2 2025 Earnings Presentation | Earnings | 33 slides | July 2025 |
| Genomma Lab Intl Sab Ord — Q1 2025 Earnings Presentation | Earnings | 58 slides | May 2, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 64 slides | March 2025 |
| Investor Presentation (May 2024) | Investor deck | 100 slides | May 2024 |
| Investor Presentation (February 2024) | Investor deck | 100 slides | February 2024 |
| Investor Presentation (August 2023) | Investor deck | 93 slides | August 2023 |
All 29 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2023) | Investor deck | 92 slides | May 2023 |
| Investor Presentation (January 2023) | Investor deck | 62 slides | January 2023 |
| Investor Presentation (July 2022) | Investor deck | 51 slides | July 2022 |
| Investor Presentation (May 2022) | Investor deck | 49 slides | May 2022 |
| Investor Presentation (September 2021) | Investor deck | 66 slides | September 2021 |
| Investor Presentation (May 2021) | Investor deck | 60 slides | May 2021 |
| Investor Presentation (September 2020) | Investor deck | 46 slides | September 2020 |
| Investor Presentation (March 2020) | Investor deck | 50 slides | March 2020 |
| Investor Presentation (November 2019) | Investor deck | 52 slides | November 2019 |
| Investor Day (November 2016) | Investor day | 55 slides | Nov 3, 2016 |
| Investor Day (November 2016) | Investor day | 55 slides | Nov 3, 2016 |
| Investor Presentation (June 2016) | Investor deck | 22 slides | June 2016 |
| Investor Day (September 2015) | Investor day | 58 slides | Sep 29, 2015 |
| Investor Day (September 2015) | Investor day | 58 slides | Sep 29, 2015 |
| Investor Presentation (September 2015) | Investor deck | 30 slides | September 2015 |
| Investor Day (November 2014) | Investor day | 77 slides | Nov 7, 2014 |
| Investor Presentation (November 2014) | Investor deck | 26 slides | November 2014 |
| Investor Presentation (November 2014) | Investor deck | 26 slides | November 2014 |
| Proxy Contest (April 2012) | Proxy contest | 26 slides | Apr 26, 2012 |
Financials
Annual, in MXN
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.5B | 18.6B | 16.5B | 16.8B | 15.5B | 13.9B | 12.7B | 11.8B | 12.1B | 11.3B |
| Cost of revenue | 6.52B | 6.68B | 6.38B | 6.66B | 5.92B | 5.28B | 4.61B | 4.03B | 3.96B | 3.64B |
| Gross profit | 11.0B | 11.9B | 10.1B | 10.2B | 9.56B | 8.59B | 8.10B | 7.76B | 8.12B | 7.68B |
| Selling, general and administrative | 7.29B | 8.06B | 6.89B | 6.92B | 6.57B | 5.67B | 5.82B | 5.58B | 5.62B | 7.49B |
| Operating income | 3.76B | 3.91B | 3.20B | 3.24B | 2.99B | 2.92B | 2.27B | 2.19B | 2.50B | 286.6M |
| Depreciation and amortization | 379.1M | 359.6M | 246.4M | 227.1M | 170.3M | 159.0M | 142.2M | 81.2M | 69.8M | 83.8M |
| EBITDA | 4.14B | 4.27B | 3.45B | 3.47B | 3.16B | 3.08B | 2.42B | 2.27B | 2.57B | 370.4M |
| Interest expense | 796.7M | 887.8M | 829.9M | 525.6M | 444.4M | 461.1M | 606.7M | 554.6M | 0 | 0 |
| Income before tax | 2.43B | 2.89B | 1.72B | 2.26B | 2.22B | 2.24B | 1.56B | 1.76B | 2.17B | -1.52B |
| Income tax | 867.6M | 914.0M | 766.8M | 795.7M | 654.0M | 758.7M | 126.5M | |||
| Net income | 1.61B | 1.49B | 1.03B | 1.39B | 1.31B | 1.47B | 764.5M | 1.11B | 1.28B | -1.68B |
| Earnings per share, basic | 1.65 | 1.58 | 1.08 | 1.44 | 1.30 | 1.44 | 0.75 | 1.09 | 1.22 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.07B | 2.38B | 1.47B | 1.50B | 1.22B | 2.05B | 899.7M | 1.39B | 1.07B | 1.85B |
| Short-term investments | 213.6M | 89.2M | 183.2M | 205.9M | 23.2M | |||||
| Receivables | 4.50B | 4.44B | 3.71B | 4.27B | 4.23B | 4.03B | 6.31B | 5.32B | 5.01B | 4.36B |
| Inventory | 1.84B | 2.18B | 1.91B | 2.40B | 2.09B | 1.94B | 1.91B | 1.70B | 1.26B | 1.17B |
| Current assets | 12.8B | 12.4B | 10.6B | 11.3B | 11.5B | 12.0B | 9.82B | 9.00B | 7.84B | 7.80B |
| Property, plant and equipment | 3.59B | 3.37B | 2.85B | 2.22B | 1.87B | 548.6M | 412.8M | |||
| Goodwill | 45.8M | 90.8M | 90.8M | 78.8M | 52.4M | 52.0M | ||||
| Total assets | 23.8B | 24.1B | 20.7B | 21.6B | 21.5B | 22.1B | 19.3B | 18.1B | 15.9B | 15.7B |
| Accounts payable | 1.58B | 1.74B | 1.84B | 1.79B | 1.44B | 1.64B | 1.88B | 1.77B | 1.10B | 1.03B |
| Current liabilities | 7.23B | 6.75B | 6.64B | 9.36B | 6.57B | 6.61B | 5.68B | 4.49B | 6.31B | 5.10B |
| Long-term debt | 4.77B | 5.06B | 4.21B | 1.55B | 3.83B | 4.45B | 4.48B | 5.20B | 1.69B | 3.76B |
| Total liabilities | 12.7B | 12.5B | 11.3B | 11.5B | 11.5B | 12.5B | 11.3B | 10.6B | 8.84B | 8.92B |
| Shareholders' equity | 11.1B | 11.6B | 9.38B | 10.2B | 10.1B | 9.63B | 7.97B | 7.43B | 6.85B | 6.58B |
| Shares outstanding | 977.8M | 944.9M | 948.0M | 964.5M | 1.00B | 1.02B | 1.02B | 1.02B | 1.05B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2.05B | 3.03B | 1.77B | 2.05B | 1.47B | 1.71B | 1.01B | 1.56B | 1.39B | 1.54B |
| Capital spending | -26.7M | -675.0M | -59.7M | -403.0M | -630.2M | -696.9M | -845.9M | -1.38B | -262.9M | -158.1M |
| Free cash flow | 2.03B | 2.36B | 1.82B | 2.04B | 1.26B | 1.71B | 130.3M | 50.2M | 1.11B | 1.39B |
| Cash from investing | -282.3M | -765.6M | -663.7M | -844.6M | -1.37B | -208.1M | 140.1M | |||
| Cash from financing | -1.36B | -1.47B | 189.8M | -622.2M | 472.9M | -1.69B | -1.65B | |||
| Dividends paid | -781.8M | -778.8M | -580.7M | -777.7M | -391.8M | -391.8M | -391.8M | -391.8M | ||
| Share buybacks | -1.88B | -1.66B | -1.90B | -994.9M | -155.8M | -15.4M | -90.9M | -133.9M | -4.01M | -1.08B |
| Change in cash | 826.3M | 710.7M | 911.6M | 239.0M | -839.0M | 1.18B | -491.7M | 321.9M | -753.5M | 30.7M |
Cap table
Built by 6ix from Genomma Lab Internacional SAB de CV Class B’s releases
- Common shares
- 977,752,666
- Fully diluted
- 977,752,666
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 977,752,666 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 977,752,666 |
Log in to ask 6ix AI your own questions about Genomma Lab Internacional SAB de CV.